EFFECTS OF INTRAVENOUS HYOSCINE BUTYLBROMIDE ON LABOUR OUTCOME AND ITS SAFETY AMONG PARTURIENTS IN LAUTECH TEACHING HOSPITAL OGBOMOSO, NIGERIA

Abstract

Background
The search for methods that shorten and thus reduce the discomfort of labour
processes without associated maternal or fetal adverse effects are still on-going.
Hyoscine butylbromide has been in use in contemporary obstetric practice but reports
supporting its efficacy in reducing the duration of labour are still conflicting.
Objective
This study is aimed at determining the effect of intravenous hyoscine butylbromide in
shortening the length of labour and its safety among the parturients.
Design
Randomized clinical trial.
Population
Consented pregnant women at term after spontaneous onset or induction of labour.
Methods
Either hyoscine butylbromide (Buscopan®) or placebo was given intravenously once the
women entered active labour (at 3 – 5cm cervical dilatation) after randomization using
computer generated numbers. Participants were evaluated using a proforma and data
obtained were entered into computer. Analysis was done with Statistical Package of
Social Sciences (SPSS) version 17.
10

Results
Two hundred and sixty (260) parturients completed the study. Of these, 128 received
hyoscine butylbromide and 132 women received the placebo. The mean age of patients
in hyoscine group was 29.77 ± 6.49 years and 28.89 ±3.94 years for placebo group. The
mean time for the first stage in the control group was 506.17±210.78 minutes,
compared with 364.73±207.10 minutes in the hyoscine group (p<0.001). There was no
statistically significant difference in the duration of the second (p = 0.757) and third
stages of labour (p = 0.137) or in APGAR scores, as well as need for SCBU admission. No
significant adverse effect was noted in the group of women receiving hyoscine
compared with the control group. More women in the hyoscine group were significantly
satisfied than placebo group following delivery (p<0.001), but no difference in pain
assessment (p=0.060) or relief score (p=0.653) in both groups.

Conclusion
Intravenous hyoscine butylbromide was effective in shortening the duration of the first
stage of labour, with no associated maternal or neonatal adverse outcomes.

EFFECTS OF INTRAVENOUS HYOSCINE BUTYLBROMIDE ON LABOUR OUTCOME AND ITS SAFETY AMONG PARTURIENTS IN LAUTECH TEACHING HOSPITAL OGBOMOSO, NIGERIA